Next Article in Journal
Impairment of Membrane Lipid Homeostasis by Bichalcone Analog TSWU-BR4 Attenuates Function of GRP78 in Regulation of the Oxidative Balance and Invasion of Cancer Cells
Previous Article in Journal
Focus on Causality in ESC/iPSC-Based Modeling of Psychiatric Disorders
Open AccessArticle

CDKI-73 is a Novel Pharmacological Inhibitor of Rab11 Cargo Delivery and Innate Immune Secretion

1
Cell Biology and Disease Research Group, Cancer Research Institute, University of South Australia, Adelaide, SA 5000, Australia
2
Centre for Drug Discovery and Development, Cancer Research Institute, University of South Australia, Adelaide, SA 5000, Australia
3
Robinson Research Institute, University of Adelaide, Adelaide, SA 5000, Australia
4
School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia
*
Authors to whom correspondence should be addressed.
Cells 2020, 9(2), 372; https://doi.org/10.3390/cells9020372
Received: 10 January 2020 / Revised: 31 January 2020 / Accepted: 3 February 2020 / Published: 5 February 2020
Innate immunity is critical for host defence against pathogen and environmental challenge and this involves the production and secretion of immune mediators, such as antimicrobial peptides and pro-inflammatory cytokines. However, when dysregulated, innate immunity can contribute to multifactorial diseases, including inflammatory rheumatic disorders, type 2 diabetes, cancer, neurodegenerative and cardiovascular diseases and even septic shock. During an innate immune response, antimicrobial peptides and cytokines are trafficked via Rab11 multivesicular endosomes, and then sorted into Rab11 vesicles for traffic to the plasma membrane and secretion. In this study, a cyclin-dependent kinase inhibitor CDKI-73 was used to determine its effect on the innate immune response, based on previously identified targets for this compound. Our results showed that CDKI-73 inhibited the delivery of Rab11 vesicles to the plasma membrane, resulting in the accumulation of large multivesicular Rab11 endosomes near the cell periphery. In addition to the effect on endosome delivery, CDKI-73 down-regulated the amount of innate immune cargo, including the antimicrobial peptide Drosomycin and pro-inflammatory cytokines interleukin-6 (IL-6) and tumour necrosis factor alpha (TNFα). We concluded that CDKI-73 has the potential to regulate the delivery and secretion of certain innate immune cargo, which could be used to control inflammation.
Keywords: CDKI-73; endosomes; Rab11; antimicrobial peptide Drosomycin; IL-6; TNFα; Drosophila CDKI-73; endosomes; Rab11; antimicrobial peptide Drosomycin; IL-6; TNFα; Drosophila
MDPI and ACS Style

Sorvina, A.; Shandala, T.; Wang, S.; Sharkey, D.J.; Parkinson-Lawrence, E.; Selemidis, S.; Brooks, D.A. CDKI-73 is a Novel Pharmacological Inhibitor of Rab11 Cargo Delivery and Innate Immune Secretion. Cells 2020, 9, 372.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop